Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
This study is currently recruiting participants.
Verified April 2013 by Indiana University
Study NCT01534260   Information provided by Indiana University

First Received on February 13, 2012.   Last Updated on April 17, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myeloid Leukemia
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Monosomy
More general conditions related to this trial
Aneuploidy
Chromosome Aberrations
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Additional drug interventions recognized in this trial
Bortezomib
Sorafenib
Vorinostat
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Indiana University
Millennium Pharmaceuticals, Inc.
Bayer
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services